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PENGHASILAN RUMUSAN NANO TERDIRI DARIPADA 
PHOSPHOLIPID-TERKANDUNG EKSTRAK STANDARD ORTHOSIPHON 
STAMINEUS UNTUK MENINGKATKAN AKTIVITI ANTIANGIOGENIK 
 
ABSTRAK 
Orthosiphon stamineus (O.S) telah dibuktikan mempunyai aktiviti 
antiangiogenik dan antitumor yang berkesan. Namun dos ekstrak yang tinggi 
diperlukan untuk mencapai kesan klinikal yang efektif. Dalam kajian ini, pendekatan 
teknologi nano menggunakan pembawa phospholipid telah diterokai untuk 
meningkatkan aktiviti antiangiogenik ekstrak O.S Hasil kajian ini menunjukkan 
bahawa nisbah 1: 1 O.S untuk phosphotidylcholine meningkatkan kesan aktiviti 
antiangiogenik ekstrak O.S formulasi tersebut. Ini menghalang pembentukan tiub 
endothelium dan penghijrahan sel dan sferoid yang dimansuhkan  kanser usus 
manusia pada potensi yang jauh lebih tinggi daripada ekstrak O.S tidak terformulasi 
tulen. Saiz zarah penggubalan mempunyai diameter purata 29 nm. Penggubalan tidak 
bagaimanapun meningkatkan penyerapan asid rosmarinik secara khusus tetapi data 
HPLC menunjukkan kehadiran rosmarinik kompleks asid-phospholipid. Data juga 
menunjukkan peningkatan kelarutan sinensitin, eupatorin dan TMF dalam tertib 
menurun kelarutan. Hasil kajian ini juga menunjukkan bahawa asid rosmarinik bukan 
komponen aktif utama O.S yang memberikan aktiviti antiangiogenik. O.S-
phospholipid kompleks dibentuk menunjukkan potensi yang melebihi asid 
rosmarinik berkenaan dengan aktiviti antiangiogenik. Kajian ini menyimpulkan satu 
formula baru yang menjanjikan O.S yang boleh meningkatkan aktiviti antitumor itu. 
xvi 
 
DEVELOPMENT OF NANO FORMULATION COMPOSED OF 
PHOSPHOLIPID-ENCAPSULATED STANDARDIZED EXTRACT OF 
ORTHOSIPHON STAMINEUS TO ENHANCE THE ANTI-ANGIOGENIC 
ACTIVITY  
 
ABSTRACT 
Orthosiphon stamineus (O.S) is a promising herb which has been shown to 
have potent antiangiogenic and antitumor activities. However, a high dose of O.S 
extract is required in order for it to be clinically effective. In this work, a 
nanotechnology based approach was adopted to enhance the antiangiogenic activity 
of O.S extract via phospholipidic carriers. The results of this study showed that a 1:1 
ratio of O.S and phosphotidylcholine significantly improved the antiangiogenic 
activity of the extract. This formulation inhibited endothelial tube formation, and cell 
migration; and abrogated human colorectal cancer spheroids with significantly higher 
potency than pure unformulated O.S extract. The formulated particles had an average 
diameter of 29 nm. Although the formulation did not increase rosmarinic acid 
absorption specifically, HPLC data indicated the presence of rosmarinic-acid-
phospholipids complexes. The data also shows increase in the solubility of sinensitin, 
eupatorin and 3’-hydroxy- 5, 6, 7, 4’-tetramethoxyflavone in an decreasing order of 
concentration. Moreover, the results of this study showes that rosmarinic acid was 
not the principal active component in O.S that conferes the antiangiogenic activity as 
O.S-phospholipids complexes shows potency which exceeded that of rosmarinic acid 
alone. The study presented a promising new formulation of O.S that may enhance its 
antitumor activity. 
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1.1. Angiogenesis 
1.1.1. Definition, and physiological and pathological mechanisms of 
angiogenesis 
Angiogenesis is the process in which pre-existing vessels develop new blood 
vessels. It is key to embryology and the development of most tumors (Wu et al., 
2002). It also plays a definite role in normal physiological functions, such as 
reproduction, repair and development (Siddiqui et al., 2009). This process can be 
regulated by some stimulators like chemokines, growth factors, some special 
angiogenic enzymes, some endothelial receptors, and adhesion molecules; and also 
by some inhibitors like angiostatin and endostatin (John et al., 2015). Imbalance 
between inhibitors and inducers levels can cause a variety of health problems, such 
as cancer, arthritis, and heart and brain ischemias; and many other diseases 
(Matsumura et al., 1997). The vascular endothelial growth factor (VEGF) is a growth 
factor which particularly incites angiogenesis (Ye et al., 1999). As VEGF plays a 
critical role in some malignant and benign cancers, it can be a suitable target for 
cancer therapy (Maeda et al., 2009). In order for new blood vessels to be formed, a 
series of physiological events need to occur. These processes include the dispersion 
of the extracellular matrix; the migration, adhesion and proliferation of endothelial 
cells; and tube formation (Ahmadi et al., 1996). 
1.1.2. Angiogenesis pathways 
Transcription factors like the hypoxia-inducible factors (HIFs) regulate more 
than 200 genes via hypoxic signaling, hence regulating cell invasion, angiogenesis 
and mitogenesis (Hawker et al., 2005). Such HIF factors also regulate some proteins, 
such as Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth 
Factor (VEGF) and Human Enhancer of Filamentation 1. VEGF is expressed in both 
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primary and metastatic human colon cancers; and  its expression is markedly high in 
metastatic cells (Ahamed et al., 2012). Thus, one of the serum markers used to detect 
colon cancer in the early stages is VEGF. In hypoxic conditions, the β and α subunits 
of HIF make dimers and translocate to the nucleus, where they regulate the 
expression of genes such as those of the vascular endothelial growth factor, 
Transforming growth factor alpha and Platelet-derived growth factor beta (Ahamed 
et al., 2012). When the amount of oxygen is normal, prolin and asparagine 
hydroxylase hydroxylate HIF-1α, setting it to  bind to VHL and later be degraded by 
proteasome (Ahmadi et al., 1996). 
1.1.3. Regulation of angiogenesis 
Angiogenesis is regulated by a strict balance between mediatory activators 
and inhibitors. There are three different regulatory stages, which involve the 
destruction of the extracellular matrix (ECM); adjustments to the levels of 
angiogenic mediators like cytokines, growth factors and some other enzymes; and 
interactions on two different levels (cell-cell and cell-matrix interactions), which 
make for the final stage of regulation of angiogenesis (Gumbiner, 1996).  
Matrix metalloproteinases (MMPs) play the main role in the degradation of 
ECM (Aisha et al., 2014). They break down the protein constituents of ECM and 
create suitable conditions for cell migration by destroying collagen and other cellular 
barriers. Hence, MMPs play a key role in tissue turn-over, which resembles a 
reaction to the environment due to the presence of physiological factors, like the 
normal growth factors, or pathological conditions, like inflammation and cancer 
(Aisha et al., 2014). MMPs activity can be regulated by two different ways, either by 
influencing its expression and activation level by manipulating proteolytic enzymes, 
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or by adjusting its level of inhibition by manipulating its inhibitors (Al-Suede et al., 
2014). 
Degradation of ECM due to the effects of different growth factors promotes 
endothelial cell migration and proliferation, which leads to the formation of new 
blood vessels (Arnaoutova et al., 2009). 
Adhesion to other cells or to their matrices represents another class of 
regulatory events in angiogenesis, which are strictly regulated in normal cell lines; as 
errors in the regulation of these events lead to different kinds of human cancers. The 
process of cell adhesion occurs with the involvement of certain adhesion molecules, 
ECM components, some endogenous inhibitors and proteolytic enzymes. 
Unfortunately, decrease in the rate of adhesion  promote cancer progression 
(Carmeliet et al., 2000). 
Adhesion molecules are categorized into 5 major protein groups: the 
selectins, the integrins, the immuneglubin superfamily, the cadherins and the 
hyaluronans groups. These proteins represent surface receptors which can be targeted 
to control cancer progression in different cancer types, and offer a variety of 
therapeutic techniques (Carmeliet et al., 2000). 
1.1.5 Tumor angiogenesis 
Angiogenesis plays a central role in tumor development. It encompasses a 
series of interactions between a wide range of intracellular mediators, leading to 
enhanced endothelial cell proliferation and invasion (Bhattaram et al., 2002). 
One of the most important modulators of pathological angiogenesis is VEGF. 
Loss of one allele of the VEGF gene can illicit major deficiencies in the vascular 
system, and is lethal in the embryonic stage (Bockhorn et al., 2007). 
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A certain percentage of somatic mutations can cause normal cells to 
proliferate continuously, transforming them into cancerous cells (Bravo et al., 2002), 
whose gradual growth leads to the formation of cancerous tumors. Exaggerated 
proliferation rates cause cells to need a greater blood supply in order for them to 
obtain more nutrients. This results in a lack of oxygen and nutrients in normal cells, 
leading to their death (Chambers et al., 1997). The spreading of tumor cells via the 
circulatory system, a process called metastasis, enables those cells to reach other 
organs in the body, causing secondary tumors (Figure 1.1). 
When a tumor grows more than its blood supply can allow, HIF-1 is 
produced, causing VEGF to be transcribed more (Chauhan et al., 2009). VEGF 
increases the permeability of blood vessels, and causes endothelial cells to migrate 
and proliferate more than usual. A lack of oxygen can also cause other pro-
angiogenic molecules, like nitric oxide synthase and PDGF, to be produced more. It 
can also affect the levels of growth factors alpha and beta, angiopoietins and the 
basic fibroblastic growth factors (bFGF) (Chaurasia et al.).  
VEGF is one of the most influential molecules which stimulate angiogenesis. 
Other regulatory molecules include: the basic fibroblast growth factor, the platelet-
derived growth factor, and metalloproteinases (MMPs). Moreover, the interferon 
family (α, β and γ), thrombospondin-1 and -2, angiostatin, and endostatin make a 
group of endogenous regulators which inhibit angiogenesis (Chen et al., 2009; Chong 
et al., 2012).   
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Figure 1.1  Mechanisms of tumor neovascularization  (Spannuth et al., 2008). 
1.1.4. Mechanisms of angiogenesis therapy 
Angiogenesis is an essential process in tumor growth and can be a suitable 
target for treatment. Hence, the purpose of using anti-angiogenic factors in cancer 
therapy is to interrupt critical stages of angiogenesis. Anti-angiogenic therapy can 
lead to reduced vessel permeability and blood perfusion, and vascular shrinkage 
which decreases the possibility of a tumor receiving oxygen and nutrients (Condeelis 
et al., 2006). Theoretically, anti-angiogenic therapy may revert tumor blood vessels 
into the normal state, and improve the quality and delivery of cytotoxic therapeutic 
agents (D’souza, 2014). Hence, anti-angiogenic agents function by reducing the 
permeability of blood vessels in tumors, and the dispersion of interstitial fluids. This 
leads to a decline in interstitial pressure, and, eventually, reduces tumor hypoxia 
(Maeda et al., 2009). If anti-angiogenic therapy is used along with cytotoxic agents, 
the effect of these agents increases, while tumor vessels are simultaneously 
normalized (Damge et al., 1990). 
A number of anti-angiogenic therapeutic agents are undergoing clinical trials. 
These agents can be classified into 3 categories: The first comprises the endothelial 
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cell growth inhibitors, the preeminent of which is endostatin. This class of 
angiogenesis inhibitors induces apoptosis and inhibits endothelial cell growth 
(Decker, 1998). The second category includes drugs which act as angiogenesis-
signaling blockers, an example of which is Avastin®. They are inhibitors of the basic 
fibroblast growth factor (bFGF) and VEGF (Folkman, 2002). The third category is 
composed of the receptor blockers which inhibit ECM destruction, like the inhibitors 
of MMPs, which act by inhibiting the receptor activities of multiple growth factors 
(Guba et al., 2002). 
1.2. Medicinal plants as a source of cancer therapeutics 
During the previous century, phytochemical research and pharmacological 
studies have been carried out on numerous herbal extracts to elucidate their chemical 
compositions and to investigate clinical manifestations associated with the use of 
herbal remedies. Traditional approaches to treat cancer employ medicines derived 
from natural sources, such as animals, minerals and herbal products.  
Plants can be used as herbal beverage, or can be extracted and their crude 
extracts may be formulated in the form of capsules or pills (Hawker et al., 2005). 
Herbal products can be used to manage a variety of health problems, including 
cancer. There is plenty of evidence indicating that phytochemical products can 
prevent the progression of cancer (Hood et al., 2002). Phytochemicals can be used by 
patients who have undergone surgery, those at risk of cancer due to family history, 
and  those undergoing chemotherapy  and suffering its side effects (Hou et al., 2012). 
1.3 Colorectal carcinoma 
According to recent research, the risk factors of colorectal cancer (CRC) include 
genetic and epigenetic mutations, chronic inflammation, a low fiber diet and an 
unhealthy lifestyle (Willett et al., 1990). Therefore, preventive measures 
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implemented to address these issues may help control this malignant disorder. In 
recent years, a lot of effort has been undertaken exploring new therapeutic 
compounds derived from natural resources for their potential in preventing and/or 
treating a variety of cancers, including CRC (Hulkower et al., 2011). 
Colon cancer is a multi-stage disease which occurs with the transformation of 
normal epithelial colon cells into invasive cells (Hüsch et al., 2013).  
Many studies have demonstrated that this multi-step process occurs due to mutations 
in adenomatous polypsis coli (APC) or cyclooxygenase-2 (COX-2) genes; mutations 
caused by Kirsten-rat sarcoma virus (K-ras mutations); a lack of the 18q21 gene; 
microsatellites disequilibrium; mutations in transforming growth factor β receptor II 
(TGFβR2); and/or the translocation and stabilization of the β-catenin gene (Jain, 
2003; John et al., 2015; Kieran et al., 2005; Kim et al., 2001; Lamalice et al., 2007; 
Li et al., 2006). 
The effect of the APC suppressor gene in the primary stages of colorectal 
carcinoma has been well studied. Gene mutations causing a loss of APC function 
are associated with an accumulation of intracellular β-catenin, which influences cell 
adhesion, and, like a transcription factor, works on the Wnt signaling pathway 
(Maeda et al., 2009). Activation of the Wnt/β-catenin signaling pathway results in 
the activation of T-cell factor/lymphoid enhancing factor-1 (TCF/LEF1), which are 
transcription factors  that promote the expression of specific target genes, like c-
Myc, cyclin D1 and COX-2, which are responsible for the tumorigenesis of 
colorectal carcinoma and a few other cancers (Mannello et al., 2001). COX-1 and 
COX-2 are different isoforms of cyclooxygenase (COX). Studies have shown that 
over expression of COX-2 leads to human colon cancer and adenomas. As the 
conversion of arachidonic acid to prostaglandins is mediated by COX-2, higher 
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levels of this enzyme may stimulate the proliferation of cancer cells, stimulate 
angiogenesis, and/or inhibit apoptosis. This is because prostaglandins promote the 
production of several growth factors, like VEGF and hepatocyte growth factor, 
which stimulate tumor angiogenesis and the proliferation of cancer cells 
(Matsumura et al., 1997). 
Other types of genetic disorders involving unstable microsatellites and 
chromosomes can also lead to carcinogenesis in the colon. Chromosomal instability 
results from a series of genetic alterations, mainly involving the stimulation of 
oncogenes like K-ras; the inactivation of tumor-suppressor genes, such as TP53 and 
APC; and the deletion of the colorectal carcinoma gene (DCC), which is located on 
chromosome 18q21. Mutations of the sort are associated with an increased risk of 
relapse and death among colon cancer patients (Misra et al., 2003). On the other 
hand, a deficient DNA mismatch-repair mechanism can lead to unstable 
microsatellites, and can increase the frequency of mutations, especially in the 
repetitive microsatellite sequences (Murugan et al., 2009). 
Colorectal cancer is highly angiogenesis-dependent; and it ranks third in 
terms of worldwide cancer incidence, preceded only by lung and breast cancers. It 
accounts for almost 10% of total cancer cases, and almost 8% of total cancer deaths 
worldwide (Murugan et al., 2009). Unfortunately, according to the World Health 
Organization (WHO), more than 70% of all cancer deaths occur in countries with 
low or middle income; and cancer-related deaths are projected to continue rising 
worldwide to reach over 11 million in 2030 (Picker et al., 2014). 
1.4 Colon cancer chemotherapy strategies 
There is no specific treatment for any of the different types of cancer to date. 
Hence, the primary aim of cancer treatment is prolonging the patient’s life 
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expectancy while ensuring a good quality of life. The principal chemotherapeutic 
agents employed in the treatment of colorectal carcinoma include cytotoxic agents, 
such as those consisting of 5-fluorouracil (5-FU), irinotecan, oxaliplatin (OX), 
leucovorin (LV) and capecitabine (Cap). Drugs representing different combinations 
of these agents, such as IFL (irinotecan, 5-FU and LV), FOLFOX (5-FU, OX and 
LV), FOLFIRI (5-FU, LV and irinotecan) and CapOx (capecitabine/oxaliplatin), 
have been studied in phase II and phase III clinical trials; and their therapeutic 
efficacies make them superior to every one of these agents alone (Sahu et al., 2015). 
Moreover, numerous combinations of monoclonal antibody agents, such as 
bevacizumab (anti-VEGF), panitumumab (human anti-EGFR) and Cetuximab 
(chimeric human-mouse anti-EGFR), and cytotoxic drugs have been studied in phase 
II and phase III clinical trials. 
 In general, the results indicated that combinations of either anti-VEGF or 
anti-EGFR antibodies and a cytotoxic agent offer a better therapeutic efficacy than 
each one of their components individually (Sahu et al., 2015). 
However, some combinations, like those involving anti-VEGF and anti-
EGFR with irinotecan, have been shown to cause a negative effect on the therapeutic 
outcome and the molecular status of tumors, reducing the availability of the wild-
type or increasing the concentration of mutant K-ras (Sahu et al., 2015). 
1.5 Herbal products as cancer treatments  
Natural drugs have been used for decades to cure several diseases. Like many 
kinds of supplementary or, sometimes, alternative treatments, most people on 
earth have for long used herbs to help themselves feel better or to gain more 
control of medical conditions like hay fever, painful bowel syndrome, menstrual 
(period) difficulties and skin problems such as eczema (Caudill, 2008; Saraf, 
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2010). A number of studies estimate that approximately 6 out of each 10 people 
with cancer (60%) use herbal products combined with conventional cancer 
therapeutic agents (Richardson et al., 2000). There are many types of therapeutic 
herbal products, several of which overlap with food items. Plants like echinacea, 
St John’s wort, green tea and ginger (Shelke, 2012) are frequently used as 
remedies.  
   There is an increasing trend worldwide for the utilization of supplementary 
natural products and complementary alternative medicine (CAM) to aid or 
substitute conventional drugs in the management of various health problems, like 
the generalized body weakness resulting from continuous use of standard 
chemotherapeutic agents (Poonthananiwatkul et al., 2015). Phytochemical 
products from plant roots, bulbs, barks, leaves, and stems as well as other herbal 
components have demonstrated potential beneficial qualities, like anti-cancer 
activities. They have even been shown to provide ingredients useful for the 
synthesis of modern drugs (Shojaei et al., 2007). A number of studies on herbal 
drugs have resulted in the identification of compounds with promising biological 
activities. Thus, investigations directed towards the determination of the proper 
dosage regimens of these herbs/compounds are highly sought to improve the 
treatment outcomes. 
1.6 Bioavailibility of phytonutrients 
Studies have shown that many naturaceutical agents, including those derived 
from natural products, demonstrate poor bioavailability when consumed orally 
(Kuhrts, 2012). For instance, the oral bioavailabilities of many compounds from 
 Eurycoma longifolia J. (Tongkat Ali), Andrographis paniculate (Hempedu Bumi), 
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and Orthosiphon stamineus  (Misai Kucing) have been found to be less than 1% 
(Bhattaram et al., 2002).  
The major bioactive compounds in O. stamineus are polyphenols and 
flavonoids (e.g. rosmarinic acid, 3',4',5,7-tetramethoxyflavone, etc.) (Siddiqui et al., 
2009). It was reported that the poor bioavailability of flavonoids was due to their 
large particle sizes and their poor  miscibility with  oils and other lipids, which is 
ought to hinder the absorption of flavonoids by the membranes of the small intestines 
(D. Singh et al., 2011; Staton et al., 2004). Lipid solubility and particle size are the 
major factors preventing certain molecules from passing through biological 
membranes and being systematically absorbed following oral administration 
(Tripathi, 2013). The effectiveness of an herbal product or medication is dependent 
upon delivering an effective level of its active compounds to the blood stream 
(Staton et al., 2004).  
Most of the bioactive phytoconstituents, like flavonoids, terpenoids, tannins, 
xanthones, polyphenols, etc. are water souble, (A. Singh et al., 2011) and, hence, 
have bad absorption prfiles (Suryawanshi, 2011).  
1.6.1 Nanotechnology in drug delivery systems 
  So far, most of the new potential therapeutics have demonstrated poor 
pharmacokinetics and biopharmaceutical properties. Therefore, enhanced drug 
delivery systems are warranted to allow the distribution of therapeutically active drug 
molecules to the site of action, while minimizing the exposure of healthy organs and 
tissues to these molecules as much as possible. Nanotechnology may serve this 
purpose by playing a key role in the development of future therapeutic agent 
“nanomedicines”. These new therapeutic agents are sought to necessitate lower doses 
13 
 
and offer better therapeutic effectiveness and safety profiles. To be considered 
efficient delivery systems, nanoparticles are supposed to be in the nanometer-size 
range, preferably between 1 and 200 nm, and must be able to contain encapsulated, 
dispersed, adsorbed, or conjugated drugs and imaging agents (Yen et al., 2009). 
1.6.2 Methods to improve bioavailability 
Low bioavailability is the major shortcoming in terms of the therapeutic 
potential of plant-based drugs. To address this issue the development of good 
formulations is required to improve the bioavailability and enhance the therapeutic 
effectiveness of such drugs. A liposome is produced by the addition of a water 
soluble compound to phosphatidylcholine (Tung et al., 2011). No chemical bonds are 
created, but it is rather that the molecules of phosphatidylcholine act as a group to 
enclose the water-soluble compound. Lots of phosphatidylcholine molecules are 
needed to surround a compound fully.Phytophospholipid conjugated herbal extracts 
(phytosome extracts) are prepared by mixing water-soluble herbal extracts with 
phosphatidylcholine, which results in the generation of chemical bonds between 
certain plant constituents and phosphatidylcholine. 1:1 or 2:1 stoichiometric 
complexes are usually what makes up phytosomes. They result from interactions 
between an extract or a phytoconstituent and a phospholipidic molecule, leading to 
enhanced absorption of bioactive constituents as compared with liposomes in which 
no interactions takes place between the herbal extract and phosphatydilcholine 
(Valster et al., 2005). Compared to phytosomes, among the few drawbacks of 
liposomes is that they are more deficult to formulate, pose higher production costs, 
and have a greater tendency to leak the encapsulated drugs. Free phospholipids are 
sometimes prone to oxidation, hydrolysis and other reactions, causing them to have 
short half lives, poor solubility, stability issues, immunogenic effects, and limited 
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target availability. They may also be rapidly cleared from the circulation as a result 
of their uptake by the reticuloendothelial system (RES), which primarily exists in the 
liver (Wu et al., 2002). On the other hand, formulations involving phytosomes have 
been shown to be safe; and their components have all been approved for 
pharmaceutical use (Di Pierro et al., 2013). 
 
Figure 0.1: Phytosome preparation method (Patel et al., 2009). 
1.6.3 Phytophospholipid complexes as drug delivery systems 
Phospholipids are useful carrier molecules utilized as a drug delivery 
technology. They are essential vehicles for the drug molecules which need to be 
administered in controlled release forms (Xu et al., 2013). The preparation of drugs 
in lipid complexes may lead to improved solubility and decreased GI toxicity 
(Yamaguchi et al., 2007). Such amphiphilic drug–lipid complexes are stable and 
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possess good bioavailability, which is why they are widely used in today´s drug 
delivery systems (Yamazaki et al., 2005). Decreased interfacial tension between a 
delivery system and GI fluids facilitates drug movement through the membranes, 
tissues, and cell walls in the organism (Ye et al., 1999). 
Phytosomes are phospholipid complexes of drugs possessing amphiphilic 
properties and hydrogen atoms capable of binding to phospholipids (Zhang et al., 
2013). Phytosomes impart better pharmaceutical and biological properties than the 
drug alone, leading to increased bioavailability (Saraf, 2010). Those complexes have 
been prepared for different non-steroidal anti-inflammatory drugs, antineoplastic 
drugs and some proteins. Formulating a drug as a phytosome complex increases its 
absorption, and minimizes its gastrointestinal toxicity (Carmeliet, 2000).  
 However, these novel carriers should have two important properties: First of 
all, they should deliver the drug at a specified rate subject to the patient’s body needs 
during treatment. Second, they should direct the active compounds in herbal drugs to 
the targeted site of action. Standard dosage forms allowing prolonged-release of a 
drug do not normally possess such properties.  
In phyto-formulation research, nano dosage forms, such as polymeric 
nanoparticles, nanocapsules, solid-lipid nanoparticles, nanoemulsions and 
phytosomes, offer some advantages, like enhanced solubility and bioavailability, 
improved pharmacological activities, and decreased toxicity. Hence, research is 
currently focused on finding ways to protect phytosomes from degradation and 
achieve better stability profiles. Herbal nano drug delivery systems are expected to 
overcome most of the problems related to herbal medicine use in the future (Saraf, 
2010), as phytosomes, which are made by binding particular components of herbal 
extracts with phosphatidylcholine, represent a dosage form with superior absorption 
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rates and better levels of effectivity compared to unformulated traditional herbal 
extracts.  
1.7 Phytophospholipid complexes overview 
1.7.1 Definition of a phytophospholipid complex 
The Greek word “phyto” signifies a plant; and “some” is often used to mean 
cell-like. Hence, a “phytosome” is an herbal cell-like construction. It refers to an 
advanced natural formula consisting of bioactive constituents of plant extracts 
encapsulated in lipid (Carmeliet et al., 2000).  
1.7.2  Rationale of phytosome formulations 
Many of the bioactive components of phytomedicines are water-soluble in 
nature. This includes flavonoids, glycosides, tannins and terpenoids. As flavonoids 
make for a large category of bioactive compounds, they have been shown to possess 
a wide range of curative activities (Carmeliet et al., 2000; Chaurasia et al.). However, 
they are improperly absorbed. This is in part due to their large molecular sizes, which 
cannot really allow them to be absorbed by passive diffusion. It is also possibly due 
to their weak lipid solubility, which significantly restricts their capability to go across 
the lipid-rich biological membranes in the human body.  
Phytosomes offer superior pharmacokinetic and pharmacodynamic profiles 
compared with traditional natural extracts. Phytosome technological innovations 
have been appropriately employed to promote the bioavailability of several 
therapeutic herbal extracts, including the extracts of milk thistle, ginkgo biloba, 
grape seeds, green tea, hawthorn, and ginseng, allowing them to be marketed for 
different medicinal applications and as nutritional supplements (Harris et al., 2010). 
Phytosomes can also be possibly utilized in pharmaceutical preparations to achieve 
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better anti-inflammatory actions and allow phytosome extract cosmetic 
combinations. 
1.8 Phytosome technology 
A phytosome forms as a micro sphere structure around a plant extract and its 
active components, and provides a protective layer against gastric secretions and gut 
bacteria alike (Patel et al., 2009). Phytosomes are obtained via a reaction between 
soy phospholipids and particular botanical derivatives in an appropriate solvent. On 
account of their physiochemical and spectroscopic 
characteristics, some complexes of the sort might possibly be considered 
novel systems of drug delivery (Koo et al., 2005). 
1.9 Characteristics of a phytosome 
1.9.1 Chemical characteristics 
A phytosome is a complex formed between an herbal product and a natural 
phospholipid, such as soy phospholipids. Basically, the choline heads of the 
phosphatidylcholine molecules bind to the herbal constituents; and then, the lipid-
soluble phosphatidyl portions, which compose the body as well as the tails of these 
molecules, envelope the choline-bound components (Shelke, 2012). However, there 
is complexity regarding the outcome of adding different stoichiometric quantities of 
a phospholipidic material to a chosen polyphenolic compound, which might be a 
simple flavonoid, in a non-polar solvent (Spannuth et al., 2008).  
1.9.2 Biological properties  
Pharmacokinetic and pharmacodynamic analyses in experimental animals and 
human subjects have been made to reveal the natural tendencies of phytosomes 
(Harris et al., 2010). The enhanced bioavailability of phytosomes in contrast with 
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non-complexed botanical derivatives continues to be the focus of researches 
worldwide (Caudill, 2008).  
1.10 Advantages of phytosomes over conventional dosage forms 
Great improvement in the bioavailability of botanical extracts can occur upon 
being formed into complexes with phospholipids. This process yields better 
absorption in the intestinal tract. It allows non-lipophillic botanical extracts to readily 
permeate the intestinal lumen, something which is, in any other case, impossible 
(Saraf, 2010).  
Phosphatidylcholine, an extremely important part of a cell’s membrane, has 
been utilized in phytosome technology to act as a carrier, and to aid in skin 
nourishment (Valster et al., 2005).  
Phytosomes are more stable than liposomes as chemical bonds are formed not 
only between the phosphatidylcholine molecules themselves but also between them 
and the phytoconstituents present (Richardson et al., 2000). Phytosomes are not to be 
mistaken for liposomes. They are structurally quite different. As opposed to a 
phytosome, a liposome is formed by combining a water-soluble compound with 
phosphatidylcholine. Not a single chemical covalent bond is created. It is rather that 
the phosphatidylcholine molecules enclose the water-soluble compound 
(Poonthananiwatkul et al., 2015). A great number of phosphatidylcholine molecules 
might be necessary to enclosing a water-soluble product. Conversely, with the 
application of a phytosome procedure, phosphatidylcholine molecules and a 
particular herbal extract basically form 1:1, or perhaps 2:1, complexes, based on the 
contents of the extract. Medicinal liposomal complexes are produced in the presence 
of water or a buffer solution. This allows the phytosomes to react with the solvent 
and obtain lower dielectric potentials (Carmeliet et al., 2000).  With regards to 
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phytosome supplements, many studies have shown that they can be significantly 
better absorbed and present significantly enhanced biological effectiveness (Saraf, 
2010).  
 
1.11 Phytophospholipid complexes in cancer chemotherapy 
Numerous dietetic vegetables, therapeutic herbs and other plants have been 
studied and their cancer chemopreventative efficacies evaluated. Consumption of 
herbal supplements may have a considerable therapeutic value in terms of reducing 
the risk of cancer and the side effects of chemotherapy (Kuhrts, 2012). Herbal 
compounds can aid in reducing the inflammatory episodes which play a critical role 
in carcinogenesis (Tripathi, 2013). It has been estimated that almost one-third of all 
cancer-related deaths in America could possibly be avoided by better dietetic choices 
(A. Singh et al., 2011). Emerging data implies that numerous dietetic agents and 
medicinal herbs can be utilized solely or in combinations alongside conventional 
chemotherapeutic agents to halt cancer progress; avoid the adverse incidence of 
cancer and metastasis; and, possibly, cure cancer (Mosmann, 1983; Yen et al., 2009). 
1.12 Traditional uses of O. stamineus 
 Orthosiphon stamineus Benth. (Lambiaceae) is an important medicinal herb 
found largely in South East Asia, where its areal parts have been traditionally used as 
remedy. Various in vitro and in vivo models have been established and utilized to 
study the bioactive phytochemicals, including the flavonoids, terpenoids and 
essential oils, present in this herb (Belcaro et al., 2013). Early traditional 
practitioners used the leaves of O. stamineus (O.S) as a diuretic, and incorporated 
them into preparations intended for the removal of kidney stones. However, later in 
time, the leaves started to be utilized to prevent and cure gallstones; rheumatism; 
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diabetes mellitus; hypertension; tonsillitis; epilepsy; menstrual disorders; gonorrhea; 
syphilis; acute and chronic nephritis; gout; osteoarthritis; and psoriasis (Ribatti, 
2011). Previous reports have demonstrated O. stamineus versatile pharmacological 
activities, which are attributable to the presence of a number of bioactive 
phytochemicals in this herb. O. stamineus possesses broad pharmacological 
properties which can be beneficial in different pathophysiological conditions. Thus, 
O.S can be considered a good candidate for further experimental and medical 
research (Willett et al., 1990). 
1.12.1 Pharmacological properties of O. stamineus 
There has been much research work on O.S which have revealed quite a 
number of interesting and important pharmacological properties of this plant. The 
pharmacological effects of O.S are attributable to the existence of polyphenols, 
glycosides, lipophilic flavones, triterpenes, and diterpenes in its extracts, presenting a 
number of bioactive compounds, such as rosmarinic acid (RA), sinensetin (SIN), 
eupatorin (EUP), betulinic acid, olenolic acid, 3′-hydroxy-5, 6, 7, 4′-
tetramethoxyflavone (TMF) and several caffeic acid derivatives (Di Pierro et al., 
2013) which have been considered to be key chemical markers that gave the 
biological activities observed (Di Pierro et al., 2013). 
A phytochemical analysis of O.S has shown a large number of chemical 
components, including monoterpenes, diterpenes, triterpenes, saponins, flavonoids, 
essential oils and several long-chain organic acids, which still need to be explored 
and identified. Pharmacological evaluation of different O.S extracts, tinctures, 
fractions, and even pure isolated compounds have shown to possess antioxidant, 
antimicrobial, anti-angiogenic, antitumor, diuretic, nephroprotective, antidiabetic, 
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antihypertensive, anti-inflammatory, anti-obesity and hepatoprotective activities 
(Yuliana et al., 2011). 
1.13 Aims and objectives 
Previously it was shown that ethanol extract of O.S can cause significant 
inhibition of angiogenesis (Ahamed et al., 2012). The studies showed that the extract 
can inhibit colon cancer in vivo and targets VEGF expression and inhibits the 
phosphorylation of the VEGFR receptor (Ahamed et al., 2012). The activity was 
found to be dose dependent and rosmarinic acid was hypothesized to be the main 
active compound given its large amount in the extract.  Other compounds present in 
the extract includes eupatorin, sinsnsetin and TMF. All these compounds as 
mentioned previously are established anti-oxidants and their bioavailability are 
limited (Akowuah et al., 2005). Thus we hypothesize that encapsulating the O.S 
extract with phospholipid may help to improve the bioavailability of the phenolic and 
flavonoids of the O.S extract and consequently can help to enhance the 
pharmacological effect, in particular antiangiogenic activity. Hence to validate this 
hypothesis, the following general objectives are being set: 
1. To develop a nano-formulation of O. stamineus extract and elucidate its 
physico-chemical properties. 
2. To enhance the antiangiogenic effect of the nano-formulation of O. stamineus 
to exceed that of  O. stamineus crude extract. 
3. To develop a drug delivery system for O. stamineus nano-formulation to 
achieve maximum bioavailability. 
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Flowchart of the research 
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Materials and instruments 
2.1.1. Materials 
Acetone Sigma-Aldrich, USA  
Agar                                          Fisher, USA 
Agarose                                            Fisher, USA  
Aluminium chloride Sigma-Aldrich, USA  
Amphotericin B (Fungizon) Sigma-Aldrich, USA  
Aprotinin Sigma-Aldrich, USA 
Betulinic acid  Sigma-Aldrich, USA  
CCD-18Co ATCC, Rockville, MD, USA  
Chloroform Riedel-de Haёn, Germany  
Crystal violet  Sigma-Aldrich, USA  
DMSO Sigma-Aldrich, USA  
DMEM medium Gibco/Life technology, UK  
ε-aminocaproic acid Sigma-Aldrich, USA  
EA.hy926 ATCC, Rockville, MD, USA  
ECGS ScienCell, USA 
